Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Arteriosclerosis, thrombosis, and vascular biology

Volumn 24, Issue 8, 2004, Pages

  Grundy, Scott M ^a   Cleeman, James I ^a   Merz, C Noel Bairey ^a   Brewer Jr , H Bryan ^a   Clark, Luther T ^a   Hunninghake, Donald B ^a   Pasternak, Richard C ^a   Smith Jr , Sidney C ^a   Stone, Neil J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MIDDLE AGED; PATIENT EDUCATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK; RISK FACTOR; STATISTICS;

AGED; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL TRIALS; COMORBIDITY; DIABETES MELLITUS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT EDUCATION; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RISK; RISK FACTORS; THROMBOLYTIC THERAPY;

EID: 8844246477     PISSN: None     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/01.atv.0000133317.49796.0e     Document Type: Conference Paper

References (45)